Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications
MWN-AI** Summary
Bruker Corporation (Nasdaq: BRKR) has announced a significant expansion of its collaboration with Noetik Inc. to enhance tissue foundational models aimed at advancing translational and therapeutic applications. This partnership follows an extensive analysis of over 3,500 patient samples using the advanced CosMx® Spatial Molecular Imager (SMI). Leveraging this sophisticated technology, Noetik aims to train bio-foundation models to simulate complex human cellular and tissue-level biology, thereby supporting therapeutic developments.
Dr. Mark R. Munch, President of Bruker NANO Group, highlighted the transformative potential of Noetik's various spatial AI models, particularly the Oncology Counterfactual Therapeutics Oracle. This innovative virtual cell technology can simulate patient biology to inform drug discovery efforts, marking a critical advancement in combating human diseases. Noetik plans to gather additional data by imaging thousands more patients with CosMx’s whole transcriptome assay, which will facilitate the development of robust models that learn from real human tissue data.
Ron Alfa, Co-Founder and CEO of Noetik, emphasized the necessity of spatial context in training foundation models. He noted that with the ingestion of high-resolution CosMx data, the models demonstrate significant scalability and enhanced capability to represent complex biological interactions. The collaboration aims to generate one billion spatially resolved human cells to advance research in oncology and other fields.
Bruker’s portfolio, which includes innovative tools like the AtoMx® SIP, CellScape™ XR, and GeoMx® DSP, continues to support groundbreaking data generation essential for translational research. The companies plan to detail these advancements at the AGBT 2026 event, underlining Bruker's commitment to enhancing scientific discovery and healthcare outcomes through innovative technology.
MWN-AI** Analysis
Bruker Corporation's expansion of its collaboration with Noetik Inc. marks a significant stride in advancing spatial biology applications, particularly in oncology. This partnership utilizes Bruker's innovative technology, the CosMx Spatial Molecular Imager (SMI), to analyze massive datasets derived from patient samples. The integration of Noetik's advanced AI models with Bruker’s platforms is anticipated to create substantial breakthroughs in drug discovery and therapeutic development.
For investors, this collaboration can be viewed as a strong bullish indicator. The increasing demand for precision medicine, especially in oncology, coupled with Noetik’s AI-driven modeling capabilities, positions both companies to thrive in a rapidly evolving market. As the healthcare landscape continues to shift towards data-driven solutions, those with robust technological foundations will gain competitive advantages. Bruker's ongoing investments and enhancements to their Spatial Biology portfolio demonstrate a commitment to remaining at the forefront of scientific innovation.
Furthermore, with Noetik's capabilities in developing foundational models using extensive spatial datasets, there’s potential for transformative outcomes that could lead to new treatment protocols. The focus on diverse therapeutic applications fosters a risk-mitigated investment strategy, as successful outcomes in cancer therapies could open up additional revenue streams.
As a strategic move, investors should monitor the adoption and integration of these technologies, particularly as Bruker presents updates at major events such as AGBT 2026. These presentations will not only showcase the advancements of their products but also provide insight into market reception and potential sales forecasts.
In conclusion, the Bruker-Noetik partnership is positioned as a promising investment opportunity in the biotechnology space. Stakeholders should consider these developments as a positive signal for future growth, profitability, and overall advancement in therapeutic applications.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx ® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications.
“Noetik’s multiple spatial AI models, including the Oncology Counterfactual Therapeutics Oracle virtual cell, which can simulate patient biology and inform drug discovery, represent transformative breakthroughs for tackling human disease,” said Dr. Mark R. Munch, President of the Bruker NANO Group. To develop self-supervised AI, Noetik leverages the CosMx SMI platform to generate the largest and most biologically complete single-cell and subcellular spatial transcriptomic and multiomic datasets in oncology.
Noetik is now further imaging thousands of additional patients with the CosMx whole transcriptome assay to train their world models that learn from human tissue data.
“Spatial context is necessary for training foundation models that truly learn human biology. We have demonstrated that our models exhibit clear scaling laws; as we ingest more high-resolution CosMx data, we see a predictable and powerful increase in the models' ability to represent complex biology. We are excited to partner with Bruker to scale toward one billion spatially resolved human cells, spanning the breadth of oncology and beyond,” said Ron Alfa, MD, PhD, Co-Founder and CEO of Noetik .
This collaboration builds on Bruker’s best-in-class spatial biology portfolio, including CosMx SMI, AtoMx ® SIP, CellScape™ XR, GeoMx ® DSP and PaintScape™ platform, which together support high fidelity data generation for discovery and translational research.
Join Bruker at AGBT 2026
Bruker will share more details on recent advancements to CosMx SMI, alongside innovations across the entire Bruker Spatial Biology portfolio, at the AGBT hospitality suite in Dade Lounge throughout the week and in their Silver Sponsor Workshop on Wednesday, February 25.
For more information, please visit www.brukerspatialbiology.com .
About Bruker Corporation – Leader of the Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com .
About Noetik
NOETIK is a frontier therapeutics company harnessing AI to deeply understand human biology and redefine clinical outcomes in oncology. Leveraging the largest proprietary multimodal oncology dataset of its kind, uniquely integrating spatial biology, NOETIK’s OCTO series of models (Oncology Counterfactual Therapeutics Oracle) precisely match therapeutic targets to patient subpopulations and accurately predict clinical efficacy. This AI-first approach elevates therapeutic development from probabilistic guesswork to precision science. By strategically partnering with clinical developers and in-licensing promising therapeutics, NOETIK accelerates the delivery of transformative cancer treatments to patients. To learn more about Noetik, visit https://www.noetik.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260224789530/en/
Bruker Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Bruker Media Contact:
Johnny Lyssand, PhD
Senior Director, Downstream Marketing
Bruker Spatial Biology
T: +1 (206) 790-2843
E: john.lyssand@bruker.com
Noetik Media Contact:
Thermal for Noetik
noetik@thermalpr.com
FAQ**
How does the expansion of Bruker Corporation BRKR's collaboration with Noetik Inc. impact the development and application of spatial AI models in oncology?
What potential advantages does Bruker Corporation BRKR anticipate from leveraging Noetik's AI-driven simulations of patient biology for drug discovery?
In what ways could the data generated from the CosMx SMI platform enhance Bruker Corporation BRKR’s existing spatial biology portfolio?
Can you elaborate on how Bruker Corporation BRKR plans to utilize the insights gained from this collaboration at the upcoming AGBT 2026 conference?
**MWN-AI FAQ is based on asking OpenAI questions about Bruker Corporation (NASDAQ: BRKR).
NASDAQ: BRKR
BRKR Trading
-3.72% G/L:
$37.425 Last:
346,982 Volume:
$37.78 Open:
